One-year trials with halofenate, clofibrate, and placebo.

Article Details

Citation

Copy to clipboard

Dujovne CA, Azarnoff DL, Huffman DH, Pentikainen P, Hurwitz A, Shoeman DW

One-year trials with halofenate, clofibrate, and placebo.

Clin Pharmacol Ther. 1976 Mar;19(3):352-9.

PubMed ID

177242 [ View in PubMed

]

Abstract

The hypolipidemic as well as other laboratory and clinical effects of halofenate, clofibrate, and placebo were compared in 29 patients with type IV hyperlipoproteinemia in a double-blind, controlled, therapeutic trial of 1 yr duration. Plasma drug levels were obtained to monitor compliance. Clofibrate and halofenate lowered serum triglycerides to a similar extent. The hypotriglyceridemic effect of halofenate was significant only when data from noncompliant patients were discarded. Only clofibrate lowered baseline levels of plasma cholesterol. Very low density lipoproteins were decreased and low density lipoproteins were increased by clofibrate but not by halofenate. Halofenate had a marked hypouricemic effect that was greater than that of clofibrate. The hypouricemic effect of halofenate and clofibrate was paralleled by a concomitant decrease in serum bilirubin. Abnormal increases in serum creatine phosphokinase were observed with both drugs primarily in patients who had abnormal initial levels.

DrugBank Data that Cites this Article

Pharmaco-metabolomics

Drug	Drug Groups	Metabolite	Change	Description
Clofibrate	Approved Investigational	Uric acid	decreased	Clofibrate decreases the level of Uric acid in the blood
Clofibrate	Approved Investigational	Cholesterol	decreased	Clofibrate decreases the level of Cholesterol in the blood
Clofibrate	Approved Investigational	Triglycerides	decreased	Clofibrate decreases the level of Triglycerides in the blood
Clofibrate	Approved Investigational	Bilirubin	decreased	Clofibrate decreases the level of Bilirubin in the blood